| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kaupinen Wes | 15% | $38,555,729 | 1,644,869 | Kaupinen Wes | 13 Dec 2024 | |||
| First Light Asset Management, LLC | 7.5% | $89,137,745 | 887,031 | First Light Asset Management, LLC | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 7.1% | -29% | $88,331,614 | -$30,366,571 | 879,009 | -26% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | -13% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 6% | +22% | $70,982,116 | +$16,164,419 | 706,360 | +29% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Samsara BioCapital, L.P. | 3.1% | -50% | $8,989,600 | -$8,989,600 | 339,743 | -50% | Samsara BioCapital, L.P. | 30 Jun 2025 |
| Dellora Investments LP | 1.3% | $3,306,892 | 141,079 | Dellora Investments LP | 13 Dec 2024 |
As of 31 Dec 2025, 139 institutional investors reported holding 9,759,432 shares of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA). This represents 82% of the company’s total 11,842,870 outstanding shares.
The largest institutional shareholders of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.5% | 892,400 | +8.5% | 2.3% | $93,407,508 |
| BVF INC/IL | 7.4% | 879,009 | -24% | 3.1% | $92,005,872 |
| Frazier Life Sciences Management, L.P. | 6.1% | 722,400 | 0% | 2% | $75,613,608 |
| First Light Asset Management, LLC | 6% | 709,141 | +31% | 5.7% | $74,225,788 |
| VANGUARD GROUP INC | 4.7% | 560,616 | +13% | 0% | $58,679,676 |
| BlackRock, Inc. | 4.7% | 559,065 | +15% | 0% | $58,517,334 |
| STATE STREET CORP | 3.6% | 420,462 | +206% | 0% | $44,009,758 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 3.3% | 389,420 | +1016% | 1.1% | $40,760,591 |
| JENNISON ASSOCIATES LLC | 3.3% | 387,483 | +262% | 0.02% | $40,557,846 |
| FEDERATED HERMES, INC. | 3.1% | 368,038 | +8.6% | 0.06% | $38,522,537 |
| Woodline Partners LP | 2.5% | 300,536 | -13% | 0.12% | $31,457,103 |
| ALLIANCEBERNSTEIN L.P. | 2.3% | 269,027 | 0.01% | $28,159,056 | |
| PERCEPTIVE ADVISORS LLC | 2.2% | 266,287 | -33% | 0.51% | $27,872,260 |
| FMR LLC | 2% | 231,760 | +110% | 0% | $24,258,346 |
| MORGAN STANLEY | 1.9% | 220,662 | +59% | 0% | $23,096,692 |
| Artisan Partners Limited Partnership | 1.8% | 211,553 | 0.03% | $22,143,253 | |
| MPM BIOIMPACT LLC | 1.7% | 205,745 | +205% | 2.5% | $21,535,329 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 178,992 | +6.5% | 0% | $18,739,109 |
| FRED ALGER MANAGEMENT, LLC | 1.3% | 150,026 | -20% | 0.06% | $15,703,221 |
| Balyasny Asset Management L.P. | 0.92% | 108,880 | -35% | 0.02% | $11,396,470 |
| SAMSARA BIOCAPITAL, LLC | 0.89% | 104,817 | -50% | 1.1% | $10,971,195 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.86% | 101,748 | 0.17% | $10,649,963 | |
| GOLDMAN SACHS GROUP INC | 0.84% | 98,935 | -58% | 0% | $10,355,526 |
| Clio Asset Management LLC | 0.77% | 91,642 | +0% | 7.4% | $9,592,168 |
| NEXTBio Capital Management LP | 0.7% | 82,686 | 0% | 5.1% | $8,654,744 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 9,759,432 | $1,021,501,695 | +$142,019,955 | $104.67 | 139 |
| 2025 Q3 | 8,525,488 | $534,466,075 | +$183,107,977 | $62.69 | 100 |
| 2025 Q2 | 5,909,706 | $133,205,244 | +$16,635,084 | $22.54 | 64 |
| 2025 Q1 | 5,123,397 | $143,404,590 | +$33,701,617 | $27.99 | 40 |
| 2024 Q4 | 4,033,052 | $48,417,227 | +$48,417,227 | $12.00 | 32 |